532321 Stock Overview
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Zydus Lifesciences Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹1,018.10 |
52 Week High | ₹1,028.45 |
52 Week Low | ₹478.45 |
Beta | 0.54 |
1 Month Change | 10.41% |
3 Month Change | 47.85% |
1 Year Change | 110.18% |
3 Year Change | 134.50% |
5 Year Change | 195.70% |
Change since IPO | 15,725.57% |
Recent News & Updates
Recent updates
Shareholder Returns
532321 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 5.0% | 2.4% | 2.3% |
1Y | 110.2% | 65.0% | 48.6% |
Return vs Industry: 532321 exceeded the Indian Pharmaceuticals industry which returned 65% over the past year.
Return vs Market: 532321 exceeded the Indian Market which returned 47.6% over the past year.
Price Volatility
532321 volatility | |
---|---|
532321 Average Weekly Movement | 3.6% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in IN Market | 10.1% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 532321's share price has been volatile over the past 3 months.
Volatility Over Time: 532321's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1952 | 23,026 | Sharvil Patel | https://www.zyduslife.com |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases.
Zydus Lifesciences Limited Fundamentals Summary
532321 fundamental statistics | |
---|---|
Market cap | ₹1.02t |
Earnings (TTM) | ₹29.56b |
Revenue (TTM) | ₹190.24b |
34.6x
P/E Ratio5.4x
P/S RatioIs 532321 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
532321 income statement (TTM) | |
---|---|
Revenue | ₹190.24b |
Cost of Revenue | ₹64.73b |
Gross Profit | ₹125.51b |
Other Expenses | ₹95.95b |
Earnings | ₹29.56b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
Earnings per share (EPS) | 29.38 |
Gross Margin | 65.97% |
Net Profit Margin | 15.54% |
Debt/Equity Ratio | 0.9% |
How did 532321 perform over the long term?
See historical performance and comparison